On August 16, 2021, Fresenius Medical Care North America (FMCNA) and Cigna announced that they expanded their value-based kidney care partnership launched in 2017. The new agreement extends the program through at least 2023. FMCNA announced that the original partnership program reduced hospitalizations by 10% compared to baseline while reducing the total cost of care for Cigna members by 3% per year. The expanded collaboration includes additional incentives that align FMCNA reimbursement with quality performance and reduction of total cost of care for Cigna members.
Under the value-based agreement with Cigna, FMCNA is paid on a fee-for . . .